GENB vs GERN

Generate Biomedicines, Inc. vs Geron Corporation — Valuation Comparison 2026

GENB

Biotechnology
Generate Biomedicines, Inc.
Quality
1.8
out of 10
Value Trap
Price
$13.09
Last close
Models
8/13
Active
VS

GERN

Biotechnology
Geron Corporation
Quality
4.6
out of 10
Value Trap
26
LOW
Price
$1.25
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType GENB Fair ValueGENB Upside GERN Fair ValueGERN Upside
Bayesian DCF Intrinsic $3.47 -73.5% $0.32 -74.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.66 -95.9% $0.28 -78.2%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $8.93 -31.7% $1.45 +15.9%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for GENB vs GERN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GENB vs GERN — Which Stock Is More Undervalued?

GERN scores higher with a 4.6/10 quality rating vs GENB's 1.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Generate Biomedicines, Inc. (GENB) and Geron Corporation (GERN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GENB currently trades at $13.09 with a QOC of 1.8/10, while GERN trades at $1.25 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).